Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: An ex vivo study

Platelets

Volumn 26, Issue 4, 2015, Pages 324-330

  Bonhomme, Fanny ^a   Bonvini, Robert ^a   Reny, Jean Luc ^a,b   Poncet, Antoine ^a   Fontana, Pierre ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Platelet function tests; Platelet transfusion; Prasugrel; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; PRASUGREL; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ADULT; ANALYTIC METHOD; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; LOADING DRUG DOSE; MALE; MIDDLE AGED; PLATELET REACTIVITY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOCYTE TRANSFUSION; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; PROCEDURES; PROSPECTIVE STUDY; THROMBOCYTE;

ACUTE CORONARY SYNDROME; ADENOSINE; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET TRANSFUSION; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 84929315329     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2015.1035247     Document Type: Article

References (40)

1. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32: 2999-3054.
2. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
3. Jakubowski JA, Payne CD, Brandt JT, Weerakkody GJ, Farid NA, Small DS, Naganuma H, Li GY, Winters KJ. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol 2006;47:377-384.
4. Husted SE, Storey RF, Bliden K, Tantry US, Høimark L, Butler K, Wei C, Teng R, Gurbel PA. Pharmacokinetics and pharmacodynam-ics of ticagrelor in patients with stable coronary artery disease: Results from the ONSET-OFFSET and RESPOND studies. Clin Pharmacokinet 2012;51:397-409.
5. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation thrombolysis in myocardial infarction 44 Trial. Circulation 2007;116:2923-2932.
6. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study. Circulation 2009;120:2577-2585.
7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
8. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
9. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R. Perioperative management of antithrombotic therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141: e326S-e350S.
10. Cattaneo M, Cerletti C, Harrison P, Hayward CPM, Kenny D, Nugent D, Nurden P, Rao AK, Schmaier AH, Watson SP, et al. Recommendations for the standardization of light transmission aggregometry: A consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Thromb Haemost 2013; 11:1183-1189.
11. Cuisset T, Cayla G, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, Morange PE, Alessi MC, Bonnet JL. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? Euro Intervention 2009;5:325-329.
12. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235.
13. Cornel JH, Becker RC, Goodman SG, Husted S, Katus H, Santoso A, Steg G, Storey RF, Vintila M, Sun JL, et al. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2012;164:334-342e1.
14. Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983; 61:1081-1085.
15. Li C, Hirsh J, Xie C, Johnston MA, Eikelboom JW. Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost 2012;10:521-528.
16. Tanguay JF, Bell AD, Ackman ML, Bauer RDC, Cartier R, Chan WS, Douketis J, Roussin A, Schnell G, Verma S, et al. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol 2013;29:1334-1345.
17. Huang PH, Croce KJ, Bhatt DL, Resnic FS. Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation. Crit Pathw Cardiol 2012;11:177-185.
18. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CAA, De Robertis E, Filipescu DC, Fries D, Görlinger K, Haas T, Imberger G, et al. Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013;30:270-382.
19. Jackson SP. The growing complexity of platelet aggregation. Blood 2007;109:5087-5095.
20. Jakubowski JA, Payne CD, Weerakkody GJ, Brandt JT, Farid NA, Li YG, Naganuma H, Lachno DR, Winters KJ. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol 2007;49:167-173.
21. Kreutz RP, Breall JA, Kreutz Y, Owens J, Lu D, Bolad I, Lohe von der E, Sinha A, Flockhart DA. Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response. Thrombosis Res 2012;130:198-202.
22. Chen L, Bracey AW, Radovancevic R, Cooper JR, Collard CD, Vaughn WK, Nussmeier NA. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 2004;128:425-431.
23. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-1834.
24. Serebruany V, Rao SV, Silva MA, Donovan JL, Kannan AO, Makarov L, Goto S, Atar D. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: Assessment by different bleeding classifications. Eur Heart J 2010; 31:227-235.
25. Vilahur G, Choi BG, Zafar MU, Viles-Gonzalez JF, Vorchheimer DA, Fuster V, Badimon JJ. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost 2007;5:82-90.
26. Farid NA, McIntosh M, Garofolo F, Wong E, Shwajch A, Kennedy M, Young M, Sarkar P, Kawabata K, Takahashi M, Pang H. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21:169-179.
27. Zafar MU, Santos-Gallego C, Vorchheimer DA, Viles-Gonzalez JF, Elmariah S, Giannarelli C, Sartori S, Small DS, Jakubowski JA, Fuster V, et al. Platelet function normalization after a prasugrel loading-dose: Time-dependent effect of platelet supplementation. J Thromb Haemost 2013;11:100-106.
28. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerabil-ity and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010;66:487-496.
29. Maillard J, Cartier Faessler V, Fontana P, Bonhomme F. Lack of effect of platelet transfusions and desmopressin on intracranial bleeding in a patient receiving Ticagrelor. A Case Rep [serial online] in press. Available: http://journals.lww.com/aacr/pages/default.aspx. DOI: 10.1213/XAA.0000000000000156.
30. Godier A, Taylor G, Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor. N Engl J Med 2015;372:196-197.
31. Hansson EC, Shams Hakimi C, Astrom-Olsson K, Hesse C, Wallen H, Dellborg M, Albertsson P, Jeppsson A. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth 2014;112:570-575.
32. Hobl EL, Derhaschnig U, Firbas C, Schoergenhofer C, Schwameis M, Jilma B. Reversal strategy in antagonizing the P2Y 12-inhibitor ticagrelor. Eur J Clin Invest 2013;43:1258-1261.
33. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: A pharma-codynamic study. J Am Coll Cardiol 2012;60:193-199.
34. Laine M, Frere C, Toesca R, Berbis J, Barnay P, Pansieri M, Michelet P, Bessereau J, Camilleri E, Ronsin O, et al. Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. Thromb Haemost 2014;111:273-278.
35. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013;61:1601-1606.
36. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5: 797-804.
37. Tanaka KA, Subramaniam K. II. Looking into the future of platelet transfusion in the presence of P2Y(12) inhibitors. Br J Anaesth 2014;112:780-784.
38. Ferreiro JL, Sibbing D, Angiolillo DJ. Platelet function testing and risk of bleeding complications. Thromb Haemost 2010;103: 1128-1135.
39. Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti D, Surgical and Clinical Outcome Research (SCORE) Group. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg 2011;91:123-129.
40. Skripchenko A, Myrup A, Awatefe H, Thompson-Montgomery D, Wagner SJ. A rest period before agitation may improve some in vitro apheresis platelet parameters during storage. Transfusion 2012;52: 1433-1438.